Date & Time
March 30, 12:00 PM ET / 9:00 AM PT
Webinar Details provided upon RSVP Approval
About the Event
Hemostemix has developed an enhanced cell therapy that restores blood flow in patients with Critical Limb Ischemia (CLI), saving 93% of limbs in a Phase 2 trial.
Join our webinar with Hemostemix CEO, Thomas Smeenk and hear about the company’s compassionate use program for CLI and the platform’s potential to treat a broad range of vascular diseases including congestive heart failure and acute myocardial infarction.